SPA
SGMT icon

Sherbrooke Park Advisers’s Sagimet Biosciences SGMT Stock Holding History

Sherbrooke Park Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$60K Buy
+10,135
New +$72.8K 0.15% 157
2024
Q4 		– Sell
-10,073
Closed -$27.9K – 1114
2024
Q3 		$27.9K Sell
10,073
-858
-8% -$2.65K 0.01% 873
2024
Q2 		$37.4K Buy
+10,931
New +$50.1K 0.01% 863

Other funds holding SGMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sherbrooke Park Advisers's SGMT Position: Q4 2025 in Review

Sherbrooke Park Advisers opened a new position in Sagimet Biosciences (SGMT) in Q4 2025: 10,135 shares worth $60K. The stake represents 0.15% of the portfolio and ranks #157 among its holdings. This is a return to the name: Sherbrooke Park Advisers previously reported a position in SGMT as recently as Q3 2024.

Sherbrooke Park Advisers first reported a position in SGMT in Q2 2024 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

  • Sherbrooke Park Advisers held 10,135 shares of Sagimet Biosciences worth $60K as of Q4 2025.
  • Sagimet Biosciences was a new Sherbrooke Park Advisers position in Q4 2025.
  • Sagimet Biosciences made up 0.15% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #157 holding.
  • Sherbrooke Park Advisers first reported a position in Sagimet Biosciences in Q2 2024 and has held it in 3 quarters since.
  • 86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.